Sensorion SA (EPA:ALSEN)
France flag France · Delayed Price · Currency is EUR
0.3640
+0.0240 (7.06%)
Jul 25, 2025, 5:35 PM CET

Sensorion Company Description

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.

The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment.

It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene.

The company was incorporated in 2009 and is headquartered in Montpellier, France.

Sensorion SA
Sensorion logo
CountryFrance
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees63
CEONawal Ouzren

Contact Details

Address:
375, rue du Professeur Joseph Blayac
Montpellier, 34080
France
Phone33 4 67 20 77 30
Websitesensorion.com

Stock Details

Ticker SymbolALSEN
ExchangeEuronext Paris
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberFR0012596468
SIC Code2834

Key Executives

NamePosition
Nawal OuzrenChief Executive Officer and Director
Laurene DanonChief Financial Officer
Bernd SchmidtChief Technical Officer
Dr. Geraldine Honnet M.D.Chief Medical Officer
Christine Le BecHead of CMC Gene Therapy
Stephanie FilipeHead of the Project Management Office
Laurent DesireHead of Preclinical Development
Rachel CooperHead of Audiology